Wave Life Sciences (WVE) is scheduled to announce Q3 earnings results on Tuesday, October 27th, before market open. The consensus EPS Estimate is -$0.32 (flat Y/Y) and the consensus Revenue Estimate ...

Sellas Life Sciences is a late-stage biotech with no product sales, hinging on its Phase 3 REGAL trial for GPS in AML. Click ...

UCSF Center for Reproductive Health and Conceivable Life Sciences today announced a collaboration and plans to establish the ...

WAVE Life Sciences (NASDAQ:WVE) outlined progress across its obesity-focused siRNA program and RNA editing pipeline during a Chardan discussion, with President and CEO Paul Bolno emphasizing the ...

A ccording to the CBRE U.S. Life Sciences Outlook 2025 report, U.S life sciences employment hit a record high in 2024, and more job growth is expected in 2025. Meanwhile, the life sciences sector ...

Buoyed by the rapid development of COVID-19 vaccines, the life sciences industry is on track for a succession of upheavals already transforming patient care, business models, and market dynamics. In ...

As costs and regulatory pressures rise and educated patients clamor for personalized treatment, digital innovations will inexorably alter the life sciences landscape. Michael Townsend, research ...

Troutman Pepper Locke has expanded its Health Care and Life Sciences Litigation Practice Group with the addition of partners ...

The team includes PhD biochemists, chemists, and biochemical engineers with experience across pharma, life sciences, software, diagnostics, and more.

The average one-year price target for Microba Life Sciences (ASX:MAP) has been revised to $0.07 / share. This is a decrease of 23.53% from the prior estimate of $0.09 dated September 29, 2026. These ...